Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

Richard Dillon*, Shanna Maycock, Aimee Jackson, Sonia Fox, Sylvie Freeman, Charles Craddock, Catherine Thomas, Emma Homer, Jane Leahy, Anna Mamwell, Nicola Potter, Nigel Russell, Andrew Wei, Hans Beier Ommen, Claire Hemmaway, Steve Knapper, Lucinda Billingham

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

34 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial'. Together they form a unique fingerprint.

Medicine & Life Sciences